Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMJTYW)

• Drug Name: Darbepoetin alfa Drug Info
• Synonyms: Aranesp (TN)

Indication

Disease Entry	ICD 11	Status	REF
Anemia	3A00-3A9Z	Approved	[1]
Carcinoma	2A00-2F9Z	Approved	[2]
Chronic kidney disease	GB61	Investigative	[3]
Nephropathy	GC2Z	Investigative	[4]

• Therapeutic Class: Antianemic Agents
• Cross-matching ID: TTD Drug ID: DMMJTYW

Molecule-Related Drug Atlas

Drug(s) Targeting Erythropoietin Receptor (EPOR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epoetin alfa	DMKWB73	Anemia	3A00-3A9Z	Approved	[6]
Methoxy polyethylene glycol-epoetin beta	DMK1LZD	Kidney transplant rejection	NE84	Approved	[7]
RHuEPO	DMALNG0	Solid tumour/cancer	2A00-2F9Z	Approved	[8]
ErepoXen	DM9YI2C	Anemia	3A00-3A9Z	Phase 3	[9]
Epoetin zeta	DM9QPOU	Anemia	3A00-3A9Z	Phase 3	[10]
Hematide	DMUE843	Anemia	3A00-3A9Z	Phase 3	[11]
Cibinetide	DMCFLRH	Depression	6A70-6A7Z	Phase 2	[12]
GlycoPEGylated erythropoietin	DM5JKCL	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[13]
Albupoietin	DMXK4CI	Anemia	3A00-3A9Z	Terminated	[14]
BBT-009	DM2YTXL	Anemia	3A00-3A9Z	Investigative	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erythropoietin Receptor (EPOR)	TTAUX24	EPOR_HUMAN	Agonist	[5]

References

• [1] Emerging treatments for traumatic brain injury. Expert Opin Emerg Drugs. 2009 Mar;14(1):67-84.
• [2] DAHANCA 10 - Effect of darbepoetin alfa and radiotherapy in the treatment of squamous cell carcinoma of the head and neck. A multicenter, open-label, randomized, phase 3 trial by the Danish head and neck cancer group. Radiother Oncol. 2018 Apr;127(1):12-19.
• [3] A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19;361(21):2019-32.
• [4] Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan. Clin Exp Nephrol. 2021 Feb;25(2):110-119.
• [5] A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9.
• [6] 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. PediatrBlood Cancer. 2009 Jul;53(1):7-12.
• [7] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
• [9] Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83.
• [10] Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008 Nov;25(11):1215-28.
• [11] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Design of Homogeneous, MonoPEGylated Erythropoietin Analogs With Preserved In Vitro Bioactivity. Exp Hematol. 2006 June; 34(6): 697-704.
• [14] Clinical pipeline report, company report or official report of cogenesys.